期刊文献+

急性心肌梗死患者血浆TAT变化的价值 被引量:5

Significance of Changes of Plasma Thrombin-antithrombin Complex in Patients with Acute Myocardial Infarction
暂未订购
导出
摘要 目的观察急性心肌梗死(AMI)患者溶栓治疗前后血浆凝血酶-抗凝血酶复合物(TAT)的变化。方法AMI患者34例,对照33例,采用双抗体夹心法检测血浆TAT;对其中6例患者溶栓前、溶栓后6 h及对12 h的血浆TAT进行动态观察,与对照组进行比较。结果AMI组TAT[(13.10±6.70)μg/l]较对照组[(6.96±3.60)μg/l]显著升高(P<0.01);6例溶栓治疗的患者;溶栓6 h后,TAT[(15.10±7.60)μg/l]较治疗前显著升高(P<0.05)。结论TAT是AMI早期诊断、治疗及预后判断的良好指标之一。 Objective To observe the changes of plasma thrombin - antithrombin complex (TAT) in patients with acute myocardial infarction (AMI) before and after intravenous thrombolytic treatment. Methods TAT level was determined by ELISA in 34 patients with AMI and 33 nomal controls. TAT was serially evaluated on admission, 6 h and 12 h after thrombolytic treatment in 6cases with AMI. The results were compared with control, Results The plasma TAT level in cases with AMI increased significantly compared with the control. TAT increased more significantly 6h after the thrombolysis. There was no significant difference in the TAT level between 12h after thrombolysis and before treatment. But it was still higher than control. Conclusions Plasma TAT is one of the good markers for AMI early diagnosis, treatment and prognosis.
出处 《实用全科医学》 2005年第6期477-478,共2页 Applied Journal Of General Practice
关键词 急性心肌梗死 血浆 凝血酶-抗凝血酶复合物 肌红蛋白 纤维蛋白 纤溶酶原 Acute myocardial infarction Thrombin - antithrombin complex Thrombolytic treatment
  • 相关文献

参考文献6

二级参考文献25

  • 1王红,李稻,李建新,王鸿利.纤溶酶-α_2-抗纤溶酶复合物单克隆抗体的制备及其应用[J].诊断学理论与实践,2002,1(1):33-36. 被引量:3
  • 2[4]Li YH, Teng JK, Tsai WC, et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction[J].J Am Coll Cardiol, 1999, 33(6):1543-1548.
  • 3[5]Cushman M,Lemaitre RN, Kuller LH,et al. Fibrinolytic activation markers predict myocardial infarction in the elderly [J].Arterioscler Thromb Vasc Biol,1999,19(3):493-498.
  • 4[6]Fareed J, Hoppensteadt DA, Laya F, et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes[J]. Clin Chem, 1998,44(Spt2):1845-1853.
  • 5[7]Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris[J]. Circulation, 1995,91(10):2520-2527.
  • 6[8]Lopez Y,Paloma MJ,Rifon J,et al. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states[J].Thromb Res, 1999, 93(2):71-78.
  • 7[9]Kienast J, Thompson SG, Raskino C, et al. Prothrombin activation fragment 1 +2 and thrombin-antithrombin Ⅲ complexes in patients with angina pectoris:relation to the presence and severity of coronary atherosclerosis [J]. Thromb Haemost, 1993, 70(4): 550-553.
  • 8Ozyilkan O,Baltali E, Ozdemir O, et al. Haemostatic changes:plasma levels of alpha 2- antiplasmin plasmin complex and thrombin antithrombin Ⅲ complex in female breast cancer[J]. Tumori,1998,84(3) : 364~367.
  • 9Kalweit GA,Feindt P,Micek M,et al. Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: comparison of plasma levels in central venous and pulmonary venous blood[J]. Thromb Res, 2000,97 (3) :105~111.
  • 10Lopez Y, Paloma MJ, Rifon J, et al. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states[J]. Thromb Res, 1999,93 (2) : 71~78.

共引文献29

同被引文献54

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部